Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 24, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,635,000 ordinary shares.
- Purchase Price: 1,330.6192 pence per share.
- Treasury Shares Held: 406,467,158 shares (representing 7.23% of total voting rights).
- Shares in Issue: 5,617,512,360 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. Following the transaction on September 24, 2007, the company's Treasury shareholding increased to 406,467,158 shares. The number of shares in issue, used as the denominator for disclosure calculations under the Financial Services Authority's rules, stands at 5,617,512,360.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,617,512,360) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (406,467,158) and its percentage of voting rights (7.23%).
- Review the specific purchase price (1,330.6192 pence) for the 1,635,000 shares acquired on September 24, 2007.